Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
Amid elevated equity–bond correlations, certain hedge fund styles are likely to improve diversification and limit downside risk, Belle Liang, chief investment officer, CIO & investment advisory, Hang Seng Bank tells FSA.
Sponsored by Loomis Sayles & Natixis
The Growth Equity Strategies Team at Loomis Sayles, an affiliate of Natixis Investment Managers, demonstrates that patience, discipline and conviction result in consistent, peer-leading risk-adjusted compounding over cycles.
The yuan-denominated corporate venture capital (CVC) fund will focus on investments across the artificial intelligence and life sciences ecosystem.
Amid elevated equity–bond correlations, certain hedge fund styles are likely to improve diversification and limit downside risk, Belle Liang, chief investment officer, CIO & investment advisory, Hang Seng Bank tells FSA.
Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
Investors have continued to push positions in tech stocks, emerging markets and North America, while cash hits a new low.
FSA looks at the best performing global equity funds over June and July amidst a volatile unwind of a crowded artificial intelligence trade.
FSA looks at the best performing global equity funds over June and July amidst a volatile unwind of a crowded artificial intelligence trade.
This week FSA compares two Asia Pacific ex-Japan equity funds: the Fidelity Asian Special Situations fund and the JPMorgan SAR Asian fund.
Investors should look beyond fashionable sectors as narrow market leadership leaves quality businesses trading at deeply discounted valuations, says Nitin Bajaj.
Investors should look beyond fashionable sectors as narrow market leadership leaves quality businesses trading at deeply discounted valuations, says Nitin Bajaj.
Sebastian Paredes, head of North Asia and CEO of DBS Bank (Hong Kong), will be retiring from executive duties.
Discounted valuations, improving policy clarity and demographic tailwinds are strengthening the case for healthcare as investors look to diversify away from ever-concentrated technology exposure, according to Yashica Reddy.
KBI Global Investors has launched a core sustainable strategy and a health and wellbeing strategy .
The new fund marks the latest addition to the wealth manager’s internal fund platform.
Portfolio manager CJ Sylvester explains his high-conviction healthcare investment strategy.
RBF II provides non-dilutive financing for healthcare companies backed by cash flow generated from sales of healthcare products and services in Asia.
This week FSA provides a quick comparison of two healthcare funds: Fidelity Global Healthcare and JPM Global Healthcare
Evolving definitions of longevity underline the need for diversification and sustainable income streams in retirement, says Manulife’s Calvin Chiu.
Tom Hancock, head of focused equity and portfolio manager of the firm’s $29bn quality strategy, tells FSA how it has managed to consistently outperform and where he currently sees opportunities.
Most healthcare investors focus on binary bets around clinical trials instead of buying profitable healthcare businesses, according to AllianceBernstein’s Vinay Thapar.
As artificial intelligence permeates through the healthcare industry, Bellevue Group favours the companies that stand to gain the most.
Janus Henderson’s Andy Acker suggests the opportunity for healthcare outperformance is becoming more promising after last year’s difficulties.
42% of fund selectors rank China as their top concern compared with 21% globally, according to Natixis Investment Managers’ survey.
The Novo Nordisk share price is up 51% over the past year, while Eli Lilly is up 84%.
After a rough ride during 2021 and 2022, the PGIM Jennison Global Opportunity fund is outperforming in 2023.
Fund managers at Janus Henderson and abrdn share why they are bullish on the healthcare sector.
Dividend kings, JP Morgan’s active drive, Wellington Management’s biopharma video, M&G’s investment mega trends, soaring hedge fund pay, Ray Dalio’s biography, Ottawa madness and much more.